Effective treatment for HIV has advanced substantially, with combination antiretroviral therapy allowing most people to achieve and maintain viral suppression when taken as prescribed. Current guidelines from recognized public health bodies recommend starting therapy as soon as possible after diagnosis, using well-studied combinations that block the virus at multiple stages of its life cycle. This article presents a neutral, antiretroviral therapy overview grounded in established guidance and recent peer-reviewed or regulatory updates.
It explains HIV drug classes comparison points, outlines ART regimen options used in practice, and reviews HIV viral suppression strategies. It also summarizes long-acting HIV therapies already authorized, next generation HIV treatments in clinical development, and HIV therapeutic research updates, including items relevant to HIV treatment guidelines 2025.
Antiretroviral therapy (ART) is the standard of care for people living with HIV. Major public health authorities recommend ART for all adults and adolescents irrespective of CD4 count, both to improve individual health and to reduce the risk of onward transmission through sustained viral suppression. The World Health Organization notes that treatment should begin as soon as possible after diagnosis, consistent with broad “treat-all” policies implemented over the past decade.
In the United States, the Department of Health and Human Services maintains living clinical guidelines that are periodically revised as new evidence emerges. The Adult and Adolescent ART guideline is regularly updated; related guidance for opportunistic infections and perinatal care carried 2025 revision dates, reflecting a continuous process of evidence review. These documents serve as key references for regimen selection, monitoring, and management of special populations.
Modern ART typically combines two or three active agents, usually including a nucleoside reverse transcriptase inhibitor (NRTI) backbone with a third drug from a different class. The objective is to suppress plasma HIV-1 RNA to below assay detection limits, preserve or restore immune function, and prevent resistance. U.S. and global guidelines emphasize baseline evaluation, attention to potential drug–drug interactions, and support for adherence to maintain suppression over time.
First-line options commonly feature an integrase strand transfer inhibitor (INSTI) due to high efficacy and tolerability. Maintenance strategies after viral suppression may include regimen simplification if appropriate, taking into account prior resistance, coinfections, and comorbidities. Ongoing monitoring includes clinical assessment and periodic measurement of HIV-1 RNA and CD4 count, per guideline-specified intervals.
NRTIs act as faulty building blocks during viral DNA synthesis, causing chain termination. They form the backbone of many initial regimens and are selected with attention to renal, bone, and metabolic profiles. Contemporary guidelines discuss multiple NRTI pairings, with selection tailored to individual characteristics and potential coinfections such as hepatitis B virus.
NNRTIs bind to reverse transcriptase at an allosteric site, inhibiting enzyme function. They can be used in initial or maintenance therapy where appropriate. Their use is guided by resistance patterns and potential interactions, as well as consideration of long-acting options that include an NNRTI component for maintenance in virologically suppressed adults.
INSTIs block integration of viral DNA into the host genome and are widely used because of favorable efficacy and tolerability profiles. They anchor many first-line combinations and also appear in long-acting maintenance regimens discussed below.
PIs inhibit viral protease, preventing maturation of new virions. They are typically used with a pharmacokinetic enhancer and may be considered in specific clinical scenarios, including certain resistance contexts or where drug–drug interactions and comorbidities permit.
Attachment and post-attachment inhibitors prevent HIV from binding to or entering host cells. Fostemsavir, an attachment inhibitor, has U.S. approval for use with other antiretrovirals in heavily treatment-experienced adults with limited options, based on studies showing durable suppression in this population. Ibalizumab, a post-attachment inhibitor administered intravenously, is indicated for adults with multidrug-resistant HIV on optimized background therapy. These agents expand options where resistance or intolerance limits conventional classes.
The capsid inhibitor lenacapavir is approved for use in heavily treatment-experienced individuals with resistant HIV, administered subcutaneously every six months in combination with an optimized background regimen. Its dosing schedule is an example of long-acting HIV therapies that extend dosing intervals for specific indications.
Most initial ART regimens combine two NRTIs with a third agent, commonly an INSTI. Alternative strategies include two-drug combinations for selected virologically suppressed adults, following a careful review of prior resistance and adherence history. Maintenance switches are considered to improve tolerability, streamline dosing, or address interactions, provided viral suppression is maintained and resistance barriers are respected. Guidance documents outline appropriate laboratory monitoring and the management of treatment failure, including resistance testing where available.
For individuals with extensive treatment experience and resistance, regimen construction may require incorporating newer classes such as attachment inhibitors, post-attachment inhibitors, or the capsid inhibitor, alongside background agents selected by susceptibility. Regulatory labeling and clinical guidance provide details on indications, dosing intervals, and monitoring considerations for these therapies.
Sustained viral suppression rests on selecting an active regimen and supporting adherence over time. Guidelines emphasize initiating therapy promptly, assessing for potential barriers, and providing ongoing counseling to optimize adherence. When viral rebound occurs, clinicians reassess adherence, evaluate for interactions or tolerability issues, and, when indicated, obtain resistance testing to guide modifications. The overarching goal is to return to or maintain HIV-1 RNA below the limit of detection using available agents with demonstrated activity.
Viral suppression strategies also involve thoughtful consideration of drug–drug interactions, especially with concomitant medications. Periodic review of renal and hepatic function and other relevant laboratory parameters informs safe, continuous therapy. When suppression is durable, maintenance switches—including to long-acting regimens for appropriately selected individuals—may be considered to support ongoing engagement in care.
Long-acting HIV therapies have expanded maintenance options for adults who are virologically suppressed and meet specific criteria. A combination of intramuscular cabotegravir (an INSTI) and rilpivirine (an NNRTI) is approved for monthly or every-two-month administration in the United States. Evidence supporting the every-two-month schedule demonstrates non-inferiority to monthly dosing at 48 weeks, providing an alternative to daily oral therapy for eligible individuals. Product labeling and published trial results outline dosing schedules, initiation procedures, and monitoring requirements.
Lenacapavir, administered subcutaneously every six months, is indicated for heavily treatment-experienced adults with multidrug-resistant HIV when used with an optimized background regimen. Although lenacapavir is also approved in 2025 for twice-yearly HIV prevention (PrEP), its treatment indication remains specific, and prevention labeling is distinct from treatment use. These developments illustrate how long-acting modalities can serve different roles across the HIV prevention-to-treatment continuum.
Clinical guidance used in many settings is periodically updated to reflect emerging evidence. In 2025, U.S. federal guideline materials included revised documents for opportunistic infections and perinatal care, while the Adult and Adolescent ART guidelines continued to be maintained as a living resource with recent updates. Globally, WHO issued updated HIV service delivery guidance in 2025, reflecting integrated, person-centered approaches to care delivery. These publications indicate a sustained focus on timely ART initiation, regimen optimization, and differentiated service delivery.
For practitioners, the practical implication is that recommended first-line and maintenance options are stable and well characterized, with incremental refinements as new data arrive. Guideline documents also address special populations, coexisting conditions, drug–drug interactions, and the use of resistance testing to inform individualized care plans within established frameworks.
Several investigational strategies aim to extend dosing intervals or reduce pill burden. A once-weekly oral combination of islatravir and lenacapavir is in Phase 3 development programs, following earlier Phase 2 data showing maintenance of viral suppression at interim time points among adults switching from standard regimens. These regimens remain investigational; safety and efficacy are evaluated in ongoing trials before any potential regulatory submissions for treatment indications.
Additional trials are evaluating once-weekly oral islatravir/lenacapavir fixed-dose combinations compared with continued standard of care among virologically suppressed adults. Study protocols specify endpoints such as maintenance of HIV-1 RNA below 50 copies/mL and include safety monitoring appropriate for long-acting or extended-interval oral agents. Until regulatory review is complete, these approaches are considered part of current HIV treatment and research rather than standard care.
HIV therapeutic research updates also include immune-based strategies. Broadly neutralizing antibodies (bNAbs) are being studied for roles in treatment intensification, maintenance, and cure-adjacent strategies such as analytic treatment interruptions under close monitoring. Research sponsored by national institutes reports that multiple bNAbs are under evaluation to target diverse viral strains, with the goal of achieving durable control without continuous daily therapy. These investigations remain experimental and are not substitutes for guideline-recommended ART.
Beyond molecules and mechanisms, international guidance continues to emphasize differentiated service delivery, integrating HIV care with other health services and tailoring visit schedules and medication refills to individual needs. WHO’s 2025 service delivery guideline reflects this trend, which supports adherence and retention while maintaining quality of care. Such models can also interface with long-acting options where available, offering varied pathways to achieve and sustain viral suppression.
Across all ART regimen options, safety monitoring is conducted according to clinical guidelines. This includes baseline and periodic laboratory testing, assessment of comorbidities, and review of concomitant medications. If virologic failure occurs, recommended steps include confirming adherence, reviewing tolerability and interactions, and obtaining resistance testing to guide adjustment of therapy. Specialized agents such as fostemsavir, ibalizumab, and lenacapavir have specific indications and dosing schedules cited in labeling, and their use is reserved for contexts described in those documents.
Long-acting HIV therapies require attention to visit schedules and injection windows to maintain therapeutic levels. Regulatory labels specify initiation steps, dosing intervals, and management of missed doses. For cabotegravir/rilpivirine, guidance includes monthly or every-two-month administration after initiation, while lenacapavir requires every six-month subcutaneous maintenance alongside an optimized background regimen for heavily treatment-experienced adults. These schedules are representative rather than exhaustive, and clinicians consult current labels and guidelines to manage timing and follow-up.
Current HIV treatment and research proceeds along two complementary tracks: consolidating proven pathways to viral suppression and exploring next generation HIV treatments that might further simplify care. On the established side, integrase-based combinations remain central, with robust evidence supporting durable suppression when taken as prescribed. On the innovation side, long-acting HIV therapies and extended-interval oral regimens are being evaluated for selected maintenance scenarios, while immune-based strategies are studied within strictly controlled protocols. Public health guidance documents are updated as results mature, and labels specify the precise contexts in which individual agents are indicated. Together, these elements define a landscape where routine care is well understood and research continues to open potential future options, all within a framework that emphasizes accuracy, clear indications, and sustained viral suppression supported by adherence and monitoring.